Kornimate/medical-research-clean huggingface dataset:
disturbances of kynurenine pathway of trytophan metabolism in schizophrenia: a quantitative reverse transcription polymerase chain reaction (rt-pcr) study

Conditions: Schizophrenia

Summary: in this pilot study, the investigators propose to characterize the pattern of activation of the kynurenine pathway of tryptophan metabolism in peripheral macrophages of patients with schizophrenia. to do this, the investigators will measure the gene expression of several major enzymes in this pathway in macrophages, including the key enzyme involved in tryptophan to kynurenine metabolism, ido, by means of quantitative reverse-transcription polymerase chain reaction (rt-pcr). the focus on enzyme mrna expression as opposed to serum or cerebrospinal fluid levels of metabolites provides a possibly more sensitive characterization of the activation of this metabolic pathway.

in this pilot study, we propose to characterize the pattern of activation of the kynurenine pathway of tryptophan metabolism in peripheral macrophages of patients with schizophrenia. to do this, we will measure the gene expression of several major enzymes in this pathway in macrophages, including the key enzyme involved in tryptophan to kynurenine metabolism, ido, by means of quantitative reverse-transcription polymerase chain reaction (rt-pcr). the focus on enzyme mrna expression as opposed to serum or cerebrospinal fluid levels of metabolites provides a possibly more sensitive characterization of the activation of this metabolic pathway. primary hypotheses: we hypothesize that patients with schizophrenia will differ in their expression of macrophage ido mrna, reflecting activation of this pathway compared to normals. we further hypothesize that patients with deficit syndrome will have higher degrees of enzyme activation. secondary hypotheses: serum tryptophan levels will be lower in patients with schizophrenia compared to controls, and they will correlate with measures of dysphoria. serum kynurenine levels will be elevated in patients with schizophrenia, particularly in deficit syndrome patients. mrna expression levels of enzymes downstream from ido will differ between patients and controls. measures of immune activation will be influenced by medical disease burden (medical comorbidities).

Eligibility criteria:
inclusion criteria: 1. diagnosis of schizophrenia, any subtype or schizoaffective disorder 2. ages 18-65 years 3. males or females 4. english speaking with ability to complete symptom ratings 5. ability to provide informed consent

Keywords: schizophrenia immune system kynurenate tryptophan metabolism nmda receptor indolamine 2,3-deoxygenase (ido)
cohort trial on perioperative localization techniques of parathyroid adenomas

Conditions: Primary Hyperparathyroidism

Summary: a prospective database of consecutive patients with hyperparathyroidism subject to surgery is created. preoperative workup and operative findings are recorded in this registry to allow comprehensive analysis.

this is a non-interventional, prospective, monocentric, non-randomized trial. all patients with biochemically confirmed primary hyperparathyroidism (phpt) who are scheduled for elective parathyroidectomy in the endocrine and digestive surgery unit of the university hospital of strasbourg are considered. data concerning the age, the operative date, the results of the pre-operative biological work-up (plasma calcium, phosphor, parathyroid hormone (pth) level, vitamin d), the results of pre-operative imaging (ct (computerized tomography) scan, 99mtc sestamibi scan, 3d-vitual neck exploration (vne)), the operative data (the surgical approach, the localization and the dimensions of the adenoma (s), the necessity to convert to classical approach and its reason, the values of the intra operative pth), the pathology results, the biological work-up at follow-up (plasma calcium, phosphor, pth, vitamin d) are prospectively recorded in the database.

Eligibility criteria:
inclusion criteria: 1. patients with biochemically confirmed phpt who are scheduled for elective parathyroidectomy 2. patient able to receive and understand trial information 3. patient affiliated with the french social security system exclusion criteria: 1. patient expressing opposition to the use, after anonymization, of medical data for scientific research 2. pregnant or breast-feeding woman 3. patient under guardianship or curatorship 4. patient under the protection of justice

Keywords: primary hyperparathyroidism parathyroidectomy 3d reconstruction virtual neck exploration
registry of long-term antithrombotic therapy-1

Conditions: Coronary Artery Disease (CAD) (E.G., Angina, Myocardial Infarction, and Atherosclerotic Heart Disease (ASHD)); Peripheral Artery Disease

Summary: to assess the rates of ischemic and hemorrhagic complications of long-term antithrombotic therapy in patients with chronic coronary syndromes

the register is a russian prospective single-center observational study of patients who have indications for long-term antithrombotic therapy in connection with chronic coronary syndromes

Eligibility criteria:
inclusion criteria: * coronary artery disease , confirmed by history of myocardial infarction, or revascularization, or definitive evidence of cad on imaging exclusion criteria: * subjects who are unwilling or unable to provide informed consent. * acute coronary syndrome within 12 months before inclusion * severe chronic heart failure (nyha iv) * stroke within 6 months before inclusion * severe liver or muscle disease * severe kidney disease / renal failure with creatinine \> 3 mg/dl * conceivable impossibility to come in touch with the patient or his family at 1-year after the intervention -

Keywords: coronary artery disease, peripheral artery disease
biopoly® rs partial resurfacing patella registry study

Conditions: Cartilage Disease

Summary: the data registry will increase the knowledge of outcomes for treatment of focal cartilage defects of the patella treated with the biopoly rs patella implant and will allow monitoring of the clinical safety and performance of the device and surgical implantation kit

the data registry will increase the knowledge of outcomes for treatment of focal cartilage defects of the patella treated with the biopoly rs patella implant this study will also allow monitoring of the clinical safety and performance of the device and surgical implantation kit

Eligibility criteria:
inclusion criteria: * age 21 years and older * cartilage lesion(s) located in the facets of the patella that have failed prior therapy (conservative or surgical) * symptomatic lesions classified as icrs grade 2, 3, or 4 * lesion size may not exceed 3.1 cm2 and must be circumscribed by a 15 mm or 20 mm circle of normal or nearly normal (icrs grade 0 or 1) cartilage, with an overall depth less than 4 mm from the articulating surface * subchondral bone quality sufficient to support the implant * understanding and willingness to comply with the post-operative rehabilitation instructions and follow-up visits. exclusion criteria: * body mass index (bmi) ≥ 35 * generalized degenerative or autoimmune arthritis * gout * uncorrected chronic malalignment of the patella (may be corrected at the same time as the implantation of the biopoly device). * uncorrected ligamentous instability (may be corrected at the same time as the implantation of the biopoly device). * kissing lesion on femur * more than one implant required to accommodate lesion * allergy to ultra-high molecular weight polyethylene (uhmwpe), or hyaluronan/ hyaluronic acid (ha) * use with opposing articulating femoral components * any concomitant painful or disabling disease of the spine, hips, or lower limbs that would interfere with evaluation of the afflicted knee * pregnant, prisoner, vulnerable population, or unable to provide informed consent.

Keywords: focal defect focal lesion chondral lesion osteochondral lesion
the model and effect assessment of training general practitioner for dementia early recognition

Conditions: Dementia

Summary: with the number of aged people increasing and the lifespan lengthen, dementia is becoming a great public challenge in china. early recognition of dementia is crucial to improve the prognosis of dementia patients and decrease the society disease burden. it is a pity that the early recognition rate of dementia is less than 7% in china. most of the aged people live in the community and general practitioners (gp) in community provide health service much more frequently than other medical workers. it is suggested that gps should be the best one to screen dementia in its early period. however, most of gps have not receive any training about dementia early recognition in china. it is imperative and meaningful to provide training to gps for improve gps' knowledge and skills about dementia early recognition. how to train gps for early recognizing dementia and how about the training effect? which training model may be better? we did not find consistent conclusion about these questions in china. this study aims to set up an effective and convenient model to training gps in dementia early recognition. a total of 152 gps in beijing will be enrolled and be randomly divided into two groups. one group will firstly have lessons about dementia early recognition and then receive face-to-face supervision and key messages by wechat about dementia early recognition once a month in the following 6 months. another group will firstly have lessons about dementia early recognition and then receive face-to-face supervision and key messages by wechat about dementia early recognition once a month in the following 3 months. the score of knowledge and attitude about dementia early recognition, the accuracy of analyzing dementia cases, the usage of dementia screening scales and the referral rate of dementia will be evaluated at different time point respectively. this study will provide evidence for training gps effectively in dementia early recognition in the future and will promote dementia early recognition in community.


Eligibility criteria:
inclusion criteria: * general practitioner on-the-job and providing outpatient service * can complete the intervention and questionnaire; * providing informed consent voluntarily. exclusion criteria: * general practitioner who may take a long-term vacation during the study * providing less than once outpatient service every week; * having no condition to use wechat; * refuse to join in this study.

Keywords: dementia early recognition general practitioner training
the "sparcol" study

Conditions: Colon Cancer; Frailty

Summary: mortality following elective colorectal cancer surgery range between 2.5-6% and increase for the elderly and frail patient regardless of t-stage. around 80% of the patients who present with a colon cancer and is in a condition where surgery is possible will be offered resection of the tumor. a part of the colon is always removed together with the lymph nodes in order to ensure that cancer cells are not left behind. the risk of lymph node metastasis is dependent on several histopathological characteristics of the tumor. the overall risk of lymph node metastases is less than 20 % in patients with early colon cancer. this indicates that the majority of patients with early colon cancer have no benefit of additional resection besides local tumor excision. the alternative to resecting a larger part of the bowel is to make more focused surgery only resecting a small part of the bowel part through a combination of laparoscopic and endoscopic techniques. this new organ sparing approach is called combined endoscopic laparoscopic surgery (cels). the investigators aimed to examinate the hypothesis that organ preserving approach (cels) provides superior quality of recovery in elderly frail patients with small colon cancers when compared with standard surgery in rct.


Eligibility criteria:
inclusion criteria: * male and female participants providing written informed consent aged 75 years and older * ps score ≥1 and /or asa score ≥3 * macroscopically or pathological colonic adenocarcinoma * clinical tnm classification t1/t2 n0 m0 * eligible and suitable for cels resection according to mdt * tumor must be located in colon, and not involving the ileac valve or taking up more than 50% of the lumen in an air-distended bowel wall exclusion criteria: * unable to give informed consent * histological high-risk features in biopsy material from tumor (mucin, signet cells, de- differentiation) * suspected other malignancy than adenocarcinoma (e.g. neuroendocrine tumors) * preoperative chemo/radiotherapy * creation of stoma perioperative * non-danish speakers

Keywords: colon cancer elderly population early colo-rectal cancer organ preserving approach combined endoscopic laparoscopic surgery (cels)
a study of the efficacy and safety of intramuscular ziprasidone followed by oral ziprasidone for the treatment of psychosis

Conditions: Schizophrenia; Mania; Delusional Disorder; Acute Exacerbation of Psychosis

Summary: to assess the efficacy, safety, and tolerability of intramuscular ziprasidone in the treatment of the acute exacerbation of non-organic psychosis of any etiology, including schizophrenia, acute mania, delusional disorder and others.


Eligibility criteria:
inclusion criteria: * hospitalized patients with psychosis * eligible for intramuscular treatment * miminum score of 60 on the panss, a score of 14 in the sum of panss excitation score and a score of at least 4 in 1 of the following items: poor control of impulses, tension, hostility, uncooperativeness or excitation. exclusion criteria: * treatment with antidepressants or mood stabilizers within seven days prior to the enrollment; for monoamine oxidase inhibitors (maois) and moclobemide, this period must be two weeks; for fluoxetine, five weeks * resistance to conventional antipsychotic agents * a history of epilepsy * a diagnosis of abuse of substance within the previous 3 months according to the dsmiv criteria.
umbilical cord mesenchymal stem cell for liver cirrhosis patient caused by hepatitis b

Conditions: Liver Cirrhoses

Summary: the study aims to evaluate the effect of allogeneic mesenchymal stem cell therapy on patients who suffered from liver cirrhosis caused by hepatitis b.

the study is investigating the effect and safety of stem cells therapy in patients with liver cirrhosis that is specifically caused by hepatitis b infection, the participants will be chosen based on inclusive and exclusive criteria to ensure the eligibility of the patients for this study. the patients will be given therapy in the form of allogeneic mesenchymal stem cells transplantation, the stem cells in this study were provided from prodia stem cell indonesia (prostem). the stem cells being will also be subjected to certain criteria to ensure the utmost safety. the data of this study will be derived from the observation results of the patients' liver damage status in weeks 4, 6 and 12. aside from that, hemodynamic will be conducted as a part of the observation

Eligibility criteria:
inclusion criteria: * patients with decompensated cirrhosis (child-pugh b) caused by hepatitis b infection (cirrhosis is evidenced by the results of ultrasonography examination and chronic hepatitis b infection is found in patients who are taking hepatitis b drugs) exclusion criteria: * patients who refuse to participate in research * having malignancies disease, both liver malignancies or other malignancies * having another co-infections such as hepatitis c and human immunodeficiency virus (hiv). * pregnant or lactation patients as evidenced by positive pregnancy test results * having complications disease such as diabetes mellitus, severe heart disease, kidney disease, and respiratory disease * having the case of alcohol dependence and nash * patients who have undergone transplantation and other stem cell therapy

Keywords: allogeneic mesenchymal stem cell umbilical cord mesenchymal stem cell liver cirrhosis due to type b hepatitis
dual energy ct vs standard triple phase ct-a randomised control trial

Conditions: Renal Cell Carcinoma; Renal Cysts; Transitional Cell Carcinoma; AML

Summary: to compare sbdect with standard triple phase multi-detector ct (tpmdct) in renal mass evaluation in terms of appropriateness of treatment received after diagnosis. to determine sbdect diagnostic accuracy.


Eligibility criteria:
inclusion criteria: * patients with suspected renal masses needing further evaluation with a contrast enhanced ct scan * patients who are referred for ct urography exclusion criteria: * patients not willing to participate in the study * age \<18 yrs * pregnant females * patients with previous h/o serious allergic reactions or contrast allergy * impaired renal function (estimated gfr\<45ml/min/mm2) * sonographically proven benign renal mass needing no further evaluation
implementation and quality assurance of dpyd-genotyping in patients treated with fluoropyrimidines.

Conditions: Adverse Drug Event; Colon Cancer; Breast Cancer; Pancreas Cancer; Rectal Cancer; Gastric Cancer; Oesophageal Cancer; Bile Duct Cancer

Summary: the purpose of this study is to examine the benefits of a clinical implementation of a dpyd-genotype test to patients starting treatment with fluoropyrimidines (fluorouracil (5-fu), capecitabine, tegafur).

patients with specific genetic mutations in the dpyd-gene have lower activity of the dihydropyrimidine dehydrogenase (dpd) enzyme, which is the rate-limiting enzyme in the metabolism of fluoropyrimidines. fluoropyrimidines are commonly used as chemotherapeutic drugs and include 5-fluorouracil, capecitabine, and tegafur. patients with decreased dpd activity are at higher risk of serious adverse events when treated with standard doses of fluoropyrimidines this study will examine the clinical implementation of the pre-emptive dpyd-genotype test. the test will analyze four of the most common genetic mutations(snps) in the dpyd-gene that leads to significant decreased dpd-activity in patients with dpyd-variant mutations, the recommended starting dose is 50%. this dose reduction will possibly reduce the rate of serious adverse events. patients who are homozygous or compound heterozygous for a dpyd-mutation will not be treated with fluoropyrimidines due to the high risk of fatal adverse effects. aim to reduce the overall incidence of severe adverse reactions(grade \>= 3) to chemotherapy regimens containing 5-fu, capecitabine, or s1 in an unselected population of colorectal, non-colorectal gi cancer, or breast cancer patients through pre-emptive dpyd-genotyping. design the investigators will conduct an open clinical trial using historical controls. the investigators will implement pre-emptive genotype testing of about 1000 consecutive patients subject to 5-fu, capecitabine, or s1 treatment for colorectal, non-colorectal gi, or breast cancer. the investigators will use a historical control group of about 500 consecutive similar patients. genotype and phenotype patients included in the study who are genotyped for dpyd will have blood collected for a post hoc phenotype test. the blood samples will be used to measure levels of uracil. some patients in the historic cohort have donated blood to an independent biobank at the time of their cancer treatment. these samples will be used for post hoc dpyd-genotype analysis after the necessary ethical approvals. cost-effectiveness an economic analysis will be undertaken to examine if implementing the dpyd-genotype is cost-effective.

Eligibility criteria:
inclusion criteria: * patients with cancer that are eligible for systemic treatment with 5-fu, capecitabine, or tegafur. exclusion criteria: * patients that earlier have been treated with 5-fu, capecitabine, or tegafur
effects of a health intervention on fear of hypoglycemia

Conditions: Health-Related Behavior; Health Education; Fear of Hypoglycemia; Impaired Awareness of Hypoglycemia; Self-Management; Type2 Diabetes Mellitus

Summary: to examine the effects of a health education intervention based on the behaviour change wheel (bcw) theory on fear of hypoglycemia and relevant outcomes of type 2 diabetic patients.

in this study, eligible participants were randomized in a 1:1 ratio into an intervention group (health education based on bcw theory given on top of regular diabetes health education) and a control group (regular diabetes health education), with a 4-week intervention period and a 8-week follow-up period, for a total of 12 weeks.

Eligibility criteria:
inclusion criteria: * comply with the 2020 chinese guidelines for the prevention and treatment of type 2 diabetes mellitus; * age ≥18 years; * duration of diabetes mellitus ≥1 year; * foh according to the elevated item endorsement criterion (e i criterion): ≥3 points on any item of the hypoglycemic fear-worry scale (hfs-ws); * patients who have the ability to listen, read, write, walk, and cooperate to complete the study; * patients who have a smart phone, and can skillfully use wechat or telephone to communicate; * voluntarily participate in this study and sign the informed consent form. exclusion criteria: * patients with comorbid acute complications or other serious diseases or disorders of consciousness, such as diabetic hypertonic state, tumors, coma, etc; * patients with comorbid psychiatric diseases or taking psychotropic drugs; * patients who have recently or are participating in other studies on similar topics.

Keywords: behaviour change wheel health educational intervention fear of hypoglycaemic impaired awareness of hypoglycaemia medical support self-management attitude type 2 diabetes mellitus
cardiovascular risk factors and intensive dietary counselling

Conditions: High Blood Pressure; Hypercholesterolemia; Tobacco Smoking

Summary: the intensive dietary counselling (idc) intervention is a prevention and health promotion activity. it is being implemented by the andalusian health service to reinforce basic intervention advice on healthy diet and exercise. the idc intervention is aimed at the prevention of diseases of the heart and blood vessels (e.g. heart failure, heart attack and stroke). the main objective of the present study is to assess adherence to the idc intervention and, consequently, its effectiveness on the prevention of the above mentioned diseases.


Eligibility criteria:
inclusion criteria: * age between 40-65 years * presence of any cardiovascular risk factors (hypertension, hypercholesterolemia, tobacco smoking, diabetes, obesity) exclusion criteria: * currently diagnosed with any vardiovascular disease * currently involved in any other clinical trial * cognitive impairment that prevents from providing an informed consent

Keywords: cardiovascular risk primary prevention intensive dietary counselling physical exercise